Immunoglobulins (Ig) are glycoproteins formed by two identical heavy and two identical light polypeptide chains. The N-terminal ends of each pair of heavy-light chains consist of two variable (V) immunoglobulin (Ig) domains (V~L~ and V~H~) that form a unique surface for antigen binding. V regions are generated during B cell ontogeny by the so-called VDJ rearrangement of the germ-line Ig genes. This genetic rearrangement allows for the tremendous initial diversity of human Igs in naïve B cells, a critical feature of the immune system, which is further increased and reshaped by somatic hyper-mutation of V regions in antigen-stimulated mature B cells.

The association of the two V domains generates the idiotype (Id), a distinctive structure and a unique collection of antigenic determinants called idiotopes. Idiotopes derive mainly from the CDR regions of the Ig V domains, frequently found to be of a conformational nature and derived from somatic mutations (**Figure [1](#F1){ref-type="fig"}**). Despite being self-proteins Ids can be immunogenic. For this reason Ids have been exploited as therapeutic immunogens in cancer treatment in two well-defined and clearly distinct contexts: (i) directly as a tumor-specific target on membrane Ig-positive malignant B cells as a consequence of their clonotypic origin, and (ii) as surrogate of tumor-associated antigen (TAA) to induce specific immune responses (**Figure [2](#F2){ref-type="fig"}**).

![**Schematic representation of an immunoglobulin (Ig).** The idiotype (Id), constituted by the variable regions of the heavy (V~H~) and light (V~L~) chains, is shown. CDRs are highlighted in red (V~H~) and blue (V~L~).](fonc-02-00159-g001){#F1}

![**(A)** Idiotype (Id) of an immunoglobulin (Ig)-expressing lymphoma cell as vaccine to induce anti-lymphoma immune response. **(B)** Schematic representation of the antigen-specific antibody (Ab1), the antigen (Ag)-mimicking anti-Ab1 anti-idiotypic antibody (Ab2), the anti-Ab2 anti-idiotypic antibody (Ab3) and their interactions. **(C)** Id of an Ab2 as vaccine to induce antigen-specific immune response to solid tumors.](fonc-02-00159-g002){#F2}

In the first case the Id itself represents the immunogen and the target on the surface of the malignant B cell. Because of their clonotypic origin the Id expressed by malignant B cells represents the only true example of tumor-specific antigen ([@B3]). Therapeutic strategies that target the unique structure of the Id of each malignant clone constitute therefore a powerful tool for the treatment of B cell malignancies ([@B7]; **Figure [2A](#F2){ref-type="fig"}**). These strategies are essentially based on the generation of an anti-Id antibody and/or T cell-based immune response by means of protein or DNA-based vaccines. The success of these approaches to eradicate established tumors or prevent their development has been largely demonstrated in animal models.

The second relevant context focuses on the use of a defined Id to induce, through a mechanism of molecular mimicry, a specific immune response against a TAA. In this case the system entails the selection of an anti-idiotypic antibody (Ab2) generated against the Id of an Ab1 specific for the TAA. The Id of the Ab2 is, in turn, used to induce an anti-idiotypic anti-Ab2 response (Ab3) that will not only recognize the immunizing Id of Ab2, but very frequently also the antigen for which the Ab1 is specific ([@B69]). The Id of Ab2 is said to carry the "internal image" of the antigen, in other words to mimic its structure, and therefore able to replace the latter for inducing the immune response (**Figures [2B](#F2){ref-type="fig"},[C](#F2){ref-type="fig"}**).

Antigen mimicry is, however, a still not-completely understood phenomenon. The concept is based on the idea that if both the antigen and the Id of the Ab2 bind to the antigen-combining site of Ab1 (paratope), then the paratope of the Ab2 would structurally resemble the antigen (**Figure [2B](#F2){ref-type="fig"}**). While in some examples structural homology between antigen and the Ab2 Id has been demonstrated to a certain extent ([@B83]; [@B26]; [@B103]; [@B25]), this is hardly the case when it comes to non-protein antigens ([@B108]). Nevertheless, irrespective of the molecular basis of mimicry, the fact is that some Ab2 induce antibodies that bind to the antigen. The strategy of active immunotherapy with anti-idiotypic vaccines has been widely explored in cancer ([@B13]; [@B69]).

Thus, an Ig Id can be conceived and used as an antigen to induce anti-Id responses in two different frameworks: (i) the Id itself as a target antigen on tumor cells, as in the case of B cell lymphomas (**Figure [2A](#F2){ref-type="fig"}**), and (ii) the Id as a mimic of a tumor antigen, with the anti-Id response ultimately intended to target the latter (**Figures [2B](#F2){ref-type="fig"},[C](#F2){ref-type="fig"}**). There is, however, an important distinction between the two cases. While the Id expressed on a tumor cell is a self-antigen, and therefore immunological tolerance is expected, this is not the case when it is used as a mimic of another antigen. In addition, Ab2 are frequently obtained in mice, for which the whole Ig is a foreign antigen for the patient. The response against the Id can thus be favored, and the constant region can act as a xenogeneic carrier. Nevertheless, in cases when the mouse antibody is not highly immunogenic immune-stimulating compounds are required to enhance the response ([@B74]).

Despite encouraging results at the preclinical level, Id-based immunotherapy has given disappointing outcomes in patients. Immunization with lymphoma Ids or anti-idiotypic antibodies mimicking tumor antigens has been demonstrated to be feasible and safe in clinical trials, despite proof of clinical efficacy is still awaited ([@B30]). As with the latter strategy ([@B43]), initial phase III clinical trials using Id vaccines in lymphoma patients did not meet their primary end points ([@B7]; [@B61]; [@B92]), highlighting the need for deeper research in both, the identification of predictors of the immune response in patients ([@B55]) and the design of clinical studies ([@B7]; [@B56]). Also, the improvement of vaccination strategies is an important issue under intense investigation ([@B13]; [@B50]; [@B92]). The last issue will be the focus of this review.

IMMUNE-STIMULATING CARRIERS AND ADJUVANTS
=========================================

In 1975, Herman Eisen reported the first case of induction of active immunity to a tumoral Id in a murine plasmacytoma model ([@B36]). Vaccination with the idiotypic protein, obtained and purified from plasma, was efficient to protect animals against subsequent tumor challenge. However, the possibility of establishing an anti-Id response in patients with Ig-secreting tumors was low, and attention turned to lymphomas where tumor cells display membrane bound Ig but secrete little. Pioneering studies in several murine lymphoma models demonstrated that the low immunogenicity of idiotypic protein can be efficiently overcome when Id was linked to a strong immunological carrier such as keyhole limpet hemocyanin (KLH). Using this approach, induction of high titers of anti-Id antibodies and protection against tumor challenge was demonstrated ([@B19], [@B20]; [@B60]; [@B42]), even in animals with established lymphoma ([@B21]), suggesting that, although nominally self-antigens, idiotypic determinants can become immunogenic when administered in a context that allows overcoming T cell tolerance. The experience gained in murine studies led to the first clinical trials of patients with low-grade, follicular lymphoma, primarily those in first remission following chemotherapy ([@B63]). While this study reported the induction of an Id-specific humoral response, neither the activation of Id-specific T cells nor clinical efficacy were described. A phase II clinical study conducted by the National Cancer Institute first demonstrated clinical efficacy upon immunization with Id protein coupled to KLH and co-administered with granulocyte-monocyte colony stimulating factor (GM-CSF). The study described the clearance of residual tumor cells and long-term disease-free survival in follicular lymphoma patients in first complete remission after standard chemotherapy ([@B8]). The correlation between Id-specific immune response and *in vivo* control of minimal residual disease was also found in a similar study conducted in Europe ([@B6]). More recently, clinical benefit associated to KLH-conjugated Id vaccines in lymphoma patients was reported in small phase II trials ([@B57]; [@B88]; [@B113]). However, clinical phase III studies aimed at obtaining regulatory approval for Id vaccines failed to reach their primary endpoints ([@B7];[@B99]). Many factors have been taken into account as possible predictors of vaccination efficacy and induction of a clinically relevant immune response. In a recent double-blind multi-center controlled phase III trial in patients with follicular lymphoma, the outcome of vaccination with the patient-specific hybridoma-derived Id was dependent on the tumor Ig isotype, with IgM being significantly more effective than IgG ([@B100]). Despite the existence of Ids with an "intrinsic" ability to generate a syngeneic immune response irrespective of the format ([@B68]), the IgM isotype has been associated with immunogenicity in contrast to the IgG ([@B89], [@B90], [@B91]), which was shown in turn, to contain epitopes in the Fc region able to activate regulatory T cells ([@B31]). With the aim of improving vaccine efficacy in patients, the possibility that Id-KLH cross-linking with glutaraldehyde may damage critical immunogenic epitopes, has prompted researchers to look for alternative reagents. Murine and patient-derived human Id-KLH vaccines generated using maleimide-based conjugation were found to be superior to glutaraldehyde conjugation to generate anti-Id immune responses ([@B59]).

Conjugation to KLH has also been used in the context of antigen-mimicking anti-idiotypic vaccines. As examples, immunization of melanoma patients with the mouse anti-idiotypic antibody MK2-23, mimicking the high molecular weight-melanoma associated antigen (HMW-MAA), was significantly more efficient in inducing anti-anti-idiotypic antibodies when conjugated to KLH and administered in association to *Bacillus Calmette-Guérin* (BCG; [@B76]). Similarly, the murine anti-idiotypic antibody 3H1, which mimics a specific epitope of carcinoembryonic antigen (CEA), when conjugated to KLH and emulsified in Freund's adjuvant was found to be able to induce effective anti-CEA immune responses in animals ([@B96]). Finally, immunization with KLH-coupled R24, a mouse monoclonal antibody (mAb) specific for the disialoganglioside 3 (GD3), which is over-expressed on transformed melanocytes, induced an anti-idiotypic cascade leading to the identification of an anti-anti-idiotypic mAb able to mediate cytotoxicity on human melanoma cells and to inhibit tumor growth in xenografted mice ([@B87]).

Apart from KLH, GM-CSF has been extensively tested in numerous protein immunization studies ([@B109];[@B29]; [@B64]), which altogether demonstrated the capacity of this cytokine to improve vaccine efficacy in terms of ability to induce Id-specific responses. The immunostimulatory properties of GM-CSF have been recently compared to those raised by CpG or IFN-α. This study demonstrated that these two last compounds are better immune adjuvants as, in contrast to GM-CSF, their administration induced efficient protection in a murine myeloma model upon vaccination with Id-KLH protein ([@B51]). Similarly, CpG co-administration significantly improved the cellular anti-CEA response in transgenic mice expressing human CEA and vaccinated with the CEA-mimicking murine 3H1 mAb (Ab2). In a CEA-transfected murine colon carcinoma cell model, the vaccine was effective in inducing protective anti-tumor immunity ([@B95]). Other cytokines that have been explored in animals, as Id-fusion proteins, include IL-2 ([@B29]; [@B117]) and IL-4 ([@B29]).

Alum, QS-21, and BCG are adjuvants that have been used in the clinics in anti-idiotypic vaccine formulations with different antigen-mimicking murine Ab2 mAbs ([@B76]; [@B38]; [@B17]; [@B43]; [@B44];[@B102]). An interesting case is the Id of 1E10 mAb, which mimics a tumor-associated type of ganglioside ([@B2]; [@B32]; [@B48]) and, when administered in patients as an anti-idiotypic vaccine (racotumomab) in alum, induces a set of antibodies that bind the ganglioside but not the 1E10 Id ([@B2]; [@B32]; [@B49]), and a ganglioside-specific cellular response ([@B46]).

IMMUNOGENIC RECOMBINANT PROTEINS
================================

Compared to hybridoma technology, the molecular rescue of the tumoral Id from patient's lymphoma cells is a less-time consuming alternative. Reverse transcription-polymerase chain reaction (RT-PCR) with family-based V gene primers allows identification and isolation of V~L~ and V~H~ region sequences directly from biopsy materials. The tumor-associated idiotypic V~L~ and V~H~ chains can then be cloned and assembled into different formats \[single chain Fv (scFv), Fab, or full-length Ig\] for expression in mammalian, bacteria, insect, or plant cells ([@B16]; [@B45]). As example, recombinant human and murine Id in scFv format produced in plants, an appealing option that allows rapid production and recovery of the recombinant protein, were found to be highly immunogenic without the need of KHL cross-linking, both in presence and in absence of adjuvant ([@B75]). scFv molecules can be also fused to immune-stimulating molecules. A fusion protein consisting of 38C13 murine B cell lymphoma scFv and tetanus toxin fragment C (FrC), produced in *E. coli* as inclusion bodies or using a cell-free protein synthesis system, induced anti-Id antibodies and was as effective as the IgM-KLH Id protein in increasing survival after tumor challenge ([@B82]).

Up to now, the only recombinant fragment assayed in the clinics in B cell lymphoma patients is the tumor Fab-Id produced in *E*. *coli* ([@B12]; [@B80]). In the case of an antigen-mimicking Ab2, the F(ab′)~2~ fragment from rat BR3E4 mAb, which mimics the colorectal carcinoma-associated epitope CO17-1A, was administered to patients coupled to KLH and showed to be more effective than the whole uncoupled IgG in inducing humoral and cellular responses ([@B18], [@B17]).

Chimeric antibodies have been assayed at the preclinical level to increase Id immunogenicity. The 1E10 mAb expressed as a chimeric mouse-human IgG1 and administered to mice in PBS alone, was immunogenic in syngeneic mice and the induced anti-idiotypic antibody response was dominant over the anti-xenogeneic human constant region response ([@B70]). In contrast, chimeric antibodies containing the 38C13 murine B cell lymphoma Id required coupling to KLH for inducing an anti-Id antibody response. However, when fused to GM-CSF, IL-2, or IL-4, these recombinant molecules elicited anti-tumor immunity when administered without carrier or adjuvant ([@B109]; [@B29]). Similarly, a fusion protein consisting of the HMW-MAA-mimicking chimeric MK2-23 Ab2 mAb linked to IL-2 was effective in enhancing immunogenicity without the need of coupling to KLH ([@B117]). Recombinant molecules containing a single xenogeneic IgG domain have also been designed for Id immunization. A bivalent Id protein, obtained by fusing the BCL1 murine B cell lymphoma scFv to the CH3 domain from human IgG1 as dimerizing unit ([@B65]), was effective in inducing anti-Id antibodies when administered either with or without adjuvant ([@B9]).

DNA VACCINES
============

Compared with Id protein vaccines, direct vaccination with DNA encoding the lymphoma Id is logistically easier to use and cheaper to manufacture. In principle, it can provide longer antigen expression to enable a sustained stimulation of both humoral and T cell-mediated immunity ([@B10]). As in the case of the Id protein, initial DNA vaccination studies in murine models showed that the tumor-derived V regions alone are poorly immunogenic, but the relatively easy manipulation of the antigen-encoding cassette has facilitated the testing of several different designs to augment immunogenicity. This has been achieved by genetically linking the Id sequence to a cytokine sequence such as GM-CSF ([@B106]) or to different CD4^+^ T cell epitope carriers. [@B62] tested plasmid-encoded Id (scFv) as a vaccine in the murine A31 B cell lymphoma and 5T33 myeloma models. Initially, only low anti-Id antibody levels and poor tumor protection were achieved when the Id was used alone. However, when the scFv gene was genetically linked to the FrC of tetanus toxin, the majority of the animals tested were protected with significant enhancement of the anti-Id antibody response. Another bacterial molecule, the B subunit of *E. coli* heat labile toxin, when fused to the BCL1 murine B cell lymphoma scFv and administered as intra-muscular injection of plasmid DNA followed by electroporation increased the antibody response against the Id and promoted survival in mice challenged with the tumor. These effects depended on the pentamerization of the fusion protein and its binding to the GM1 ganglioside ([@B27]). On the same line, in the 38C13 murine B cell lymphoma model, [@B106] showed that provision of a DNA construct encoding a constant region of human Ig linked to the Id gene was required for specific induction of anti-Id antibodies. Moreover, vaccination with an Id-GM-CSF fusion construct resulted in enhancement of both anti-Id antibody levels and tumor protection. The scFv-Id gene was also fused to a DNA encoding an immuno-enhancing peptide derived from IL-1β and demonstrated induction of tumor immunity that protected mice from tumor challenge ([@B47]). An alternative fusion gene between a scFv and a protein derived from a plant virus was described as a further way to provide T cell epitopes and induce protective immunity in lymphoma and myeloma ([@B98]).

Although scFv is a popular format for the design of recombinant Id-based vaccines ([@B62]), dimeric proteins are frequently constructed by fusing the scFv with a dimerizing unit ([@B11]; [@B40]). In fact, bivalency was reported to be important for efficient anti-Id antibody induction and T cell activation by a scFv-based vaccine ([@B39]). In the BCL1 model the fusion of the scFv to the xenogeneic CH3 domain from human IgG1 was found to efficiently induce anti-Id antibodies and protection upon tumor challenge ([@B11]). The minimal immunizing unit that has been assayed is the heavy chain CDR3 (H-CDR3). A vaccine based on Id H-CDR3 fused to tetanus toxin FrC was protective in the 38C13 murine B cell lymphoma model ([@B58]).

One particularity of DNA vaccination is that the immunizing molecule is *per se* immunostimulatory. The non-immunogenic 1E10 mAb Id, in the context of a fusion protein with CH3 domain from mouse IgG1 (i.e., with no xenogeneic carrier), induced a clear anti-idiotypic response by gene gun DNA immunization. The adjuvant properties of bacterial DNA seemed to be responsible for this outcome, as when the same recombinant construct was administered through recombinant adeno-associated virus (rAAV) infection no response at all was detected ([@B67]). In a contrasting result, the xenogeneic human IgG3 hinge/CH3 were required for good antibody responses and tumor protection in the murine MOPC315 myeloma and A20 B cell lymphoma models, with a DNA vaccine encoding the respective dimeric scFv-Id fused to the MIP-1α chemokine, administered by intramuscular injection followed by electroporation. When the syngeneic counterparts were used, the vaccine failed to elicit protective immunity ([@B39]).

VIRAL VECTORS
=============

Administration of naked DNA has the disadvantage that a large amount of the immunogen is degraded before entering the cells ([@B33]). The use of virus-based vectors can partially circumvent this problem allowing the efficient penetration of cells while mimicking natural infection ([@B28]). Concerning the employment of viral vectors as vehicle to Id delivery *in vivo*, preclinical studies were performed in two murine B cell lymphoma models (38C13 and BCL1) to address the vaccine efficacy of Id-encoding adenoviruses ([@B110]). It was demonstrated in both models that a single injection of Id-adenovirus provided protection from subsequent tumor challenge, which was equivalent, or superior to that obtained by standard Id-KLH protein vaccine. However, this protection was dependent on the inclusion of xenogeneic Ig constant region. The ability of recombinant adenovirus encoding a lymphoma Id gene to induce humoral and T cell-mediated anti-Id responses was evaluated also in the A20 murine B cell lymphoma model. A single vaccination with an adenoviral vector encoding a scFv derived from the lymphoma tumor Id coupled to the human IgG1 Fc (Ad.A20hFc) elicited a specific anti-Id antibody response and protection in challenged animals ([@B4]).

Among non-replicative viruses, adeno-associated viruses (AAV) have been extensively explored as transgene delivery vectors for their capacity to infect mainly non-dividing cells, such as muscle cells, and to induce a long-term expression of the transgene. The potentiality of these vectors for immunotherapeutical purposes has been intensely explored ([@B73]; [@B34]; [@B66]; [@B119]). Overall, these studies demonstrated the reliable capacity of recombinant AAV (rAAV) to induce specific immunity to foreign antigens upon intramuscular, subcutaneous, and oral administration. In this regard, we explored the possibility to induce anti-Id immune responses by means of rAAV-mediated vaccinations. We demonstrated that immunization with two recombinant vectors, encoding the BCL1 murine B cell lymphoma scFv (Id^BCL1^) fused to the human IgG1 CH3 domain (Id^BCL1^/CH3), induced significant anti-Id antibody titers one month from rAAV injection ([@B24]). However, while a single intra-muscular injection of rAAV-Id^BCL1^/CH3 produced efficient tumor rejection *in vivo*, anti-Id antibody titers were significantly lower compared to previous standard immunizations consisting of repetitive administration of plasmid DNA by gene gun. Interestingly, when biolistic and rAAV immunization were combined in a prime-boost vaccination regimen the anti-Id immune response was further improved with a concordant increase in tumor protection. The mechanism that drives the efficacy of the prime-boost phenomenon is not clearly identified. In most cases, the huge amount of antigen supplied by the recombinant virus, in this case rAAV, seems to guarantee a more robust expansion of the antigen-specific immune response primed by the initial vaccination with naked DNA.

TARGETING OF ANTIGEN-PRESENTING IMMUNE CELLS
============================================

Alternative ways to enhance immunogenicity of Ids have been investigated to overcome the need of chemical cross-linking and adjuvants that may have deleterious side effects. Among them, immunization with autologous dendritic cells (DCs) pulsed with the Id protein or *in vivo* targeting of antigen-presenting cells (APCs) were tested. The first approach produced encouraging results in different clinical trials ([@B52]; [@B111]). A combination of sequential administration of pulsed DCs and of Id-KHL protein, was also found to be efficient in inducing both humoral and cellular anti-lymphoma Id immunity ([@B53]). A more recent study reported the induction of protective immunity in two lines of transgenic mice by pulsing DCs with an anti-idiotypic antibody (6D12) mimicking Her-2/neu antigen ([@B97]).

In an alternative setting, Id vaccines have been targeted to APCs by fusion with chemokines, CD40-ligand (CD40L) or antibodies specific for APC-restricted molecules (**Figure [3](#F3){ref-type="fig"}**). In a pioneering study, two chemokines, IP-10 and MCP-3, were N-terminally fused to the Ids from two different lymphoma models in the scFv format, and delivered as plasmid DNA or purified proteins ([@B15]). The fusions elicited strong immune responses that protected from tumor challenge in both models and with both chemokines. The adjuvant effect was supposed to be due to targeting of the antigen to professional APCs where the receptor for chemokines is expressed. This view was suggested by the requirement of a physical link between the scFv-Id antigen and the functionally active chemokine. Using a similar vaccine design, the same group demonstrated that the chemokine fusion facilitates the presentation of the tumor Id by APC via the MHC class II pathway ([@B14]). Other chemokines have been exploited as targeting unit for APC priming, such as MIP-1α and RANTES. The presence of a xenogeneic dimerizing unit (human IgG3 CH3 domain) was found to be essential in inducing protective immune response in mice immunized with a vaccine consisting of the tumor Id fused to MIP-1α or RANTES chemokines ([@B39]). A DNA vaccine consisting of the A20 murine B cell lymphoma Id in scFv format fused to the MCP-3 chemokine and administered in sites pretreated with cardiotoxin had a higher impact on overall survival of challenged mice than the scFv alone. The presence of the myotoxin, which recruited APCs by promoting sterile inflammation, was also advantageous for the efficacy of the vaccination ([@B85]).

![**Antigen-presenting cell (APC)-targeting strategies.** Antigen is delivered to APC by antibodies specific to APC-restricted molecules or internalizing receptors, or by APC-specific ligands. Antigen is efficiently internalized, processed and presented to activate CD4+ and/or CD8+ T cells.](fonc-02-00159-g003){#F3}

Targeting of antigen to APCs can be achieved also by antibodies or scFv specific for APC-restricted molecules. A DNA immunogen encoding a bivalent tumor Id and an anti-MHC class II scFv antibody was able to induce in mice higher levels of anti-Id antibodies than in control animals that had received an unrelated targeting unit or in animals not expressing the specific class II allele. The immune response led to tumor protection in two murine models, the MOPC315 myeloma and the A20 B cell lymphoma ([@B40]). It was demonstrated a superior priming capacity of APC derived from draining lymph nodes to activate antigen-specific T cells *in vitro* when animals were vaccinated with the MHC class II-specific plasmid. Concordantly, antigen-specific CD4^+^ T cells in lymph nodes were found to be more activated in these animals, consistent with a targeting effect due to enhanced uptake of protein by APC and presentation to CD4^+^ T cells. The same prototype construct, encoding a myeloma patient-derived Id, efficiently induced in mice specific anti-Id responses that were patient-specific and dependent on the targeting effect ([@B41]).

CD40 has been also exploited as APC-targeting receptor. Fusion of a chimeric antibody containing the 38C13 murine B cell lymphoma Id to CD40L improved immunogenicity compared to administration of the antibody alone, to levels similar to those of an Id/GM-CSF fusion protein ([@B54]). *In vivo* targeting of CD40^+^ APCs with a vaccine consisting on the A20 murine B cell lymphoma Id chemically conjugated to an anti-CD40 antibody induced more efficient tumor protection than a classic vaccination with Id-KLH plus GM-CSF. Monophosphoryl lipid A but not GM-CSF had a synergistic effect with the Id conjugated to the antibody ([@B22]).

Recently, the 38C13 murine B cell lymphoma-derived scFv-Id was linked, in a diabody format, to a B cell targeting moiety constituted by an anti-CD19 scFv. The recombinant molecule was proven to bind to non-cognate B cells, which in turn stimulated Id-specific B cells. Animals vaccinated with this diabody developed potent Id-specific antibody and T cell responses comparable to those induced by 38C13-KLH. Interestingly, such diabodies were produced in a cell-free protein expression system that allowed the preparation of proper amounts of vaccine in a few hours ([@B81]).

ANTIBODIES VERSUS T CELL RESPONSES
==================================

The evidences accumulated so far on tumor protection induced by anti-Id immunization do not allow to clearly define the main mechanism involved in the rejection of tumor cells. The understanding of this issue is of major relevance, since this may allow improving vaccine efficacy and prognosis of lymphoma patients.

In mouse models, protein-based vaccines were shown to work through an anti-Id antibody-dependent mechanism ([@B86]; [@B112]) or through the induction of effector T cells ([@B15]). In human studies, clinically relevant immune responses induced by immunization with Id-protein or Id-pulsed DCs were dependent on the induction of Id-specific CD8^+^ T cells ([@B8]). Moreover, synthetic peptides derived from Ig framework region shared among lymphoma patients were able to induce cytotoxic responses ([@B114]). These evidences indicated that malignant B cell can process and present class I-restricted peptides derived from Ig framework V regions. The study of [@B57] clearly reported the induction of a humoral and cytotoxic cellular immune response against Id in lymphoma patients immunized with KLH-coupled Id in association with GM-CSF.

Upon DNA immunization, the *in vivo* antigen synthesis and processing should favor the loading of antigenic peptides onto MHC class I molecules and the induction of cytotoxic T lymphocyte (CTL) responses only if the delivered DNA construct is expressed by APCs, which depends on the method of DNA delivery. However, by using a chimeric mouse/human IgG DNA vaccine delivered by intramuscular injection, it was shown that protection in the 38C13 murine B cell lymphoma model was not impaired by CD4^+^/CD8^+^ T cell depletion ([@B107]).

Similarly, we demonstrated that anti-Id antibodies, were totally essential to confer tumor protection in the BCL1 murine B cell lymphoma model ([@B23]), despite the fact that DNA was intradermally delivered by gene gun immunization, a method that allows expression of antigen also by dermal resident DCs (our unpublished observations). However, since we did not deplete any T cell subpopulation, a possible contribution of protective T cells in this model, in addition to antibodies, cannot be completely ruled out.

On the contrary, in the 38C13 as well as in the A20 murine B cell lymphoma models, protection was found to be dependent on CD4^+^ and CD8^+^ T cells, when animals were vaccinated with a DNA construct encoding the scFv-Id fused to two different chemokines ([@B15]). In addition, cytotoxic cell lines, with proliferative and cytotoxic activity against the A20 murine B cell lymphoma cell line, were efficiently generated from mice vaccinated with a scFv adenoviral vaccine ([@B4]). Interestingly, in some cases Id-specific CD4^+^ T cells have been found to be unique players in tumor rejection. In the murine A31 B cell lymphoma and 5T33 myeloma models, protection induced by DNA vaccination with a scFv fused to potato X virus protein was clearly compromised upon *in vivo* depletion of CD4^+^ T cells ([@B98]). Another study performed on this issue showed that tumor protection against B lymphoma cells was induced in absence of B cells, antibodies and CD8^+^ T cells in a T cell receptor (TCR)-transgenic mouse model specific for an MHC class II-restricted peptide of the λ2 Ig light chain derived from the MOPC315 plasmacytoma ([@B71]).

Considering clinical trials, a positive correlation between anti-Id antibody response and overall survival was found in patients with follicular lymphoma receiving the Id-KLH plus GM-CSF vaccine. In contrast, the T cell response was not associated with clinical outcome, although this was attributed to the variability of the cellular assays ([@B1]). In a trial with an Id vaccine in the Fab format, the cellular response correlated with higher progression-free survival in the group of patients receiving the vaccine as first line treatment, but not in those immunized after remission consolidation following chemotherapy ([@B80]). Previous studies had indicated an association between T cell responses and clinical benefit ([@B8]; [@B57]). In any case, the induction of Id-specific CTLs is almost always a desired feature. The use of GM-CSF in current clinical vaccine formulations is indeed directed to achieve this goal. Several patients enrolled in clinical trials developed T cell responses against the immunizing Id ([@B72]; [@B92]). T cell specificities were mapped to peptides derived from the CDRs of V~H~ ([@B80]). Induction of V~H~-CDR3-specific CTLs was also achieved when immunizing mice with a plasmid encoding this peptide fused to tetanus toxin FrC ([@B58]). In fact, DNA immunization is an excellent tool to induce cellular responses ([@B105]).

Another strategy to achieve cellular responses against the immunizing Id is vaccination with Id-pulsed DCs. In a small trial, autologous DCs incubated with the Id and KLH and re-administered to the patients activated T cells specific for the Id in half of them, although the relative contribution of Th1 and Th2 compartments in this response was not defined ([@B94]). However, it has also been reported that immunization with DCs pulsed with conserved idiotopes shared by different Ids (i.e., peptides from J regions) can lead to activation of regulatory T cells and thus dampen the response against Id-specific idiotopes such as H-CDR3 peptides ([@B118]). In another approach, a shift toward Id-specific Th1 response was achieved in the A20 murine B cell lymphoma model using a complex mixture containing: the Id DNA, MIP3-α chemokine, and a small interfering RNA to silence IL-10. This formulation induced CTL activation and protection after tumor challenge ([@B101]).

Furthermore, the anti-tumor effect of the MCP-3 chemokine-scFv DNA vaccine in combination with cardiotoxin was dependent on the cellular response, as it was abrogated after T cell depletion, but independent of the humoral response, as protection was also achieved in B cell-deficient mice ([@B85]).

In the case of human antigen-mimicking Ab2 used in the clinics, the Id is neither foreign nor strictly self, but syngeneic. It has been suggested that for T cell responses the presence of the human Fc could be advantageous ([@B35]). The 105AD7 mAb, which mimics the complement regulatory protein CD55 ([@B103]) was obtained by the heterohybridoma technique using lymphocytes from a colorectal cancer patient administered, for diagnostic purposes, with an anti-tumor mouse mAb ([@B5]). Vaccination of colorectal ([@B93]; [@B115]) and osteosarcoma ([@B84]; [@B116]) patients with 105AD7 mAb in alum alone or with BCG in the first immunization ([@B115]), either failed to induce an anti-anti-idiotypic antibody response ([@B93]; [@B115]) or induced a weak response against CD55 ([@B84]), but it was able to activate both anti-Ab2 and anti-CD55 T cell responses ([@B115], [@B116]).

In one study B lymphocytes from a patient with colorectal cancer treated with a mouse mAb, specific for the epithelial-cell adhesion molecule (Ep-CAM), were immortalized with Epstein--Barr virus to isolate anti-idiotypic antibodies ([@B104]). A pool of these Ab2, given in alum either unconjugated or conjugated to immunogenic peptides from the *Bordetella pertussis* toxin subunit S1, induced humoral and cellular responses against the antibodies and the Ep-CAM antigen ([@B37]). In another study immunization with the antigen or the Ab2 mAb with GM-CSF as adjuvant was compared. While both immunogens generated specific T cell responses, the Ab2 mAb did not induce anti-Ep-CAM antibodies ([@B78]). The induction of antigen-specific T cell responses was later confirmed in a trial where the recombinant antigen, the Ab2 mAb and a combination of both, also with GM-CSF, were tested ([@B79]). Interestingly, in a preclinical study with Ep-CAM-expressing transgenic mice, the Ab2 protein vaccine was more efficient than the Ab2 DNA vaccine for the anti-anti-idiotypic antibody response. In the genetic strategy, fusion to GM-CSF but not the presence of a xenogeneic Fc region, enhanced the antibody response against the Ab2 ([@B77]).

CONCLUSION
==========

Although the Id of Igs is nominally a self-antigen and consequently poorly immunogenic, strategies intended to induce anti-Id immune responses have successfully demonstrated the feasibility of breaking tolerance against Ids, both in animal models and in the human context. The employment of adjuvants, carriers, viral vectors, or the direct recruitment of immune-related cells has allowed translating Id targeting by the immune system into therapeutic approaches for Ig-expressing tumors (**Table [1](#T1){ref-type="table"}**). Treatment of several other malignancies can also involve Id-based vaccination, taking advantage of antigen mimicry by Ids. Solid evidences of clinical benefit are however still awaited, and more work is needed to unveil the mechanisms and factors that impact on the generation of therapeutic anti-Id immune responses.

###### 

Summary of some vaccine designs to foster anti-Id immune response discussed in the text.

                                     Id-vaccine design                                                         Target                                           Reference
  ---------------------------------- ------------------------------------------------------------------------- ------------------------------------------------ ---------------------------------------
  Carrier and adjuvants              Tumor Ig coupled to KLH + GM-CSF                                          Human lymphoma                                   [@B8], [@B6], [@B57], [@B88], [@B113]
                                     Tumor Ig coupled to KLH + CpG/IFN-α                                       5TGM1 murine myeloma                             [@B51]
  Immunogenic recombinant proteins   Tumor scFv fused to TT-FrC                                                38C13 murine B cell lymphoma                     [@B82]
                                     Tumor scFv fused to human γ1 CH3                                          BCL1 murine B cell lymphoma                      [@B9]
                                     Tumor Fab + GM-CSF                                                        Human lymphoma                                   [@B12], [@B80]
                                     Chimeric tumor Ig fused to GM-CSF, IL-2, IL-4                             38C13 murine B cell lymphoma                     [@B109], [@B29]
  DNA vaccines                       Tumor Id H-CDR3 fused to TT-FrC                                           38C13 murine B cell lymphoma                     [@B58]
                                     Tumor scFv fused to TT-FrC                                                Murine A31 B cell lymphoma and 5T33 myeloma      [@B62]
                                     Tumor scFv fused to the coat protein of Potexvirus                        Murine A31 B cell lymphoma and 5T33 myeloma      [@B98]
                                     Tumor scFv fused to human γ1 CH3                                          BCL-1 murine B cell lymphoma                     [@B11]
                                     Tumor scFv fused to B subunit of *E. coli* heat labile toxin              BCL-1 murine B cell lymphoma                     [@B27]
                                     Chimeric tumor Ig fused to GM-CSF                                         38C13 murine B cell lymphoma                     [@B106]
  Viral vectors                      Tumor scFv fused to human γ1 CH3 in adeno-associated virus vector         BCL-1 murine B cell lymphoma                     [@B24]
                                     Chimeric tumor Ig in adenovirus vector                                    Murine 38C13 and BCL-1 B cell lymphomas          [@B110]
  APC-loading/targeting              Tumor scFv fused to IL-1β-derived peptide                                 38C13 murine B cell lymphoma                     [@B47]
                                     Tumor scFv fused to IP-10 or MCP-3                                        Murine 38C13 and A20 B cell lymphomas            [@B15]
                                     Tumor scFv fused to MCP-3 + cardiotoxin                                   A20 murine B cell lymphoma                       [@B85]
                                     Tumor scFv fused to human γ3 CH3-hinge and to MIP-1α or RANTES            Murine A20 B cell lymphoma and MOPC315 myeloma   [@B39]
                                     Tumor scFv fused to human γ3 CH3-hinge and to an anti-MHC class II scFv   Murine A20 B cell lymphoma and MOPC315 myeloma   [@B40]
                                     Tumor scFv fused to an anti-CD19 scFv (diabody)                           38C13 murine B cell lymphoma                     [@B81]
                                     Chimeric tumor Ig fused to CD40L                                          38C13 murine B cell lymphoma                     [@B54]
                                     Tumor Ig chemically conjugated to an anti-CD40 antibody                   A20 murine B cell lymphoma                       [@B22]
                                     Tumor Ig-loaded DCs                                                       Human lymphoma                                   [@B52], [@B111]

Id, idiotype; Ig, immunoglobulin; KLH, keyhole limpet hemocyanin; GM-CSF, granulocyte macrophage--colony stimulating factor; CpG, oligodeoxynucleotides containing unmethylated CG dinucleotides; IFN-α, interferon alpha; scFv, single-chain variable fragment; TT-FrC, tetanus toxin fragment C; IL-2, interleukin 2; IL-4, interleukin 4; Fab, antigen binding fragment; H-CDR3, heavy chain complementary-determining region 3; IL-1β, interleukin 1 beta; IP-10, interferon inducible protein 10; MCP-3, monocyte chemotactic protein 3; MIP-α, macrophage inflammatory protein 1 alpha; RANTES, regulated and normal T cell expressed and secreted; CD40L, CD40-ligand; DCs, dendritic cells; MHC, major histocompatibility complex.
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